Tag: mental health treatments

  • Study: Psychedelics Change The Way People With Depression Read Faces

    Study: Psychedelics Change The Way People With Depression Read Faces

    Researchers believe that even one dose of a psychedelic could change the way that people read facial expressions.

    Psychedelics may help alleviate the symptoms of depression and anxiety by making sufferers more adept at reading other people’s facial expressions, according to a recent review of scientific studies.

    The review, published in the journal Therapeutic Advances in Psychopharmacology, looked at eight previous studies that examined the effects of psychedelics. The authors of the review found that psychedelics changed how people read facial expressions, and that change had an effect on their symptoms of mental illness.

    “Our most consistent finding was that these drugs reduced the recognition of negative emotions and modulated amygdala activity to these stimuli. This effect was correlated with antidepressive effects in depressed patients,” study authors wrote.

    They noted that the pool they reviewed was small, so there is a need for further review. Still, they said the results were promising.

    “Despite the small sample sizes, results suggest that serotonergic hallucinogens show promising beneficial effects on deficits in recognition of emotions in facial expressions,” they wrote.

    People with depression and anxiety often have unusual patterns of social cognition, in particular when it comes to interpreting other people’s facial expressions.

    “Some studies show that people with anxiety and mood disorders have deficits in the recognition of facial expressions,” study authors wrote. “For example, in social anxiety disorder, which is characterized by fear of undergoing criticism or negative judgment in social situations, there is hypervigilance to facial expressions of fear, sadness, and joy, and these expressions act as indicators of threat or social reinforcement according to the phenotype of the disorder.”

    Researchers found that even one dose of a psychedelic could change the way that people read facial expressions, and help alleviate depression symptoms.

    “Indeed, the studies reviewed showed that a single dose or a few doses of LSD or psilocybin was associated with a modified pattern of recognition of negative emotions that could be interpreted as beneficial, since several of these studies showed that these modifications were correlated with increases in positive mood and/or anxiolytic and antidepressant effects,” the study authors wrote.

    Psychedelics weren’t the only drugs that changed emotional facial perceptions. The study authors also found that MDMA (ecstasy) has similar effects.

    “There is also evidence that the serotonergic drug MDMA consistently reduces identification of negative emotions in tasks of face recognition and decreases the activity of the amygdala,” they wrote, adding that this could be similar to the way pharmaceutical antidepressants work.

    ”These mechanisms, associated with the capacity of MDMA to enhance serotonergic tone in the prefrontal cortex, could be shared mechanisms with traditional antidepressants and classic hallucinogens for emotional regulation in subjects with mood and anxiety disorders.”

    View the original article at thefix.com

  • Doctors Put Woman In Deep Coma To Treat Her Depression And It Worked

    Doctors Put Woman In Deep Coma To Treat Her Depression And It Worked

    The woman said she noticed a significant difference after the second treatment.

    People suffering from severe depression oftentimes don’t feel like they care if they live or die. That’s the state that Heather B. Armstrong was in when she agreed to participate in an experimental depression treatment that induced a deep coma to try to reset the brain and treat her depression. 

    “If it means I don’t have to feel this way through the rest of my life, let’s maybe do it?” Armstrong said of the treatment in an interview with The New York Post

    The treatment mimics brain death by inducing a deep coma for 15 minutes at a time over 10 sessions. This “burst suppression” essentially shuts down the brain’s neurological communications before starting them back up, resetting neurological functions that may contribute to symptoms of depression. Doctors who help anesthetize patients call the deep sedations “the abyss.”

    Armstrong wrote about her experience in a new book, The Valedictorian of Being Dead: The True Story of Dying Ten Times to Live.

    “Quieting is a polite way of saying ‘taking down to zero,’” Armstrong writes. 

    Although the thought of the treatment was terrifying—doctors used the anesthetic propofol to sedate Armstrong and the opioid fentanyl to help her cope with headaches induced by the process—Armstrong quickly saw results

    “It was after the second treatment when I suddenly realized, ‘Oh, I showered without even thinking about it!’ After the third treatment… I started doing my hair and wearing cleaner clothes,” she said.

    Halfway through the treatment cycle, “I was sitting outside watching my kids playing, and I actually felt happy,” she said. 

    Armstrong wasn’t alone in her success. She was one of 10 people who took part in a study run by the University of Utah Neuropsychiatric Institute. Of those, six people experienced significant relief from their depression symptoms.

    Doctors believe the treatment works in a similar way to electroconvulsive therapy (ECT) by targeting the brain’s neural networks. However, the treatment appears to avoid common complications of ECT, including memory loss

    Researcher Dr. Brian J. Mickey said in the afterword of Armstrong’s book. “This study… could be the beginning of something new, but the true benefits of Propofol for treatment-resistant depression remain unknown. Much work still needs to be done.”

    It has now been two years since Armstrong underwent the treatments, and she says that her depression symptoms have stayed at bay. By undergoing brain death again and again, she has rediscovered life. 

    “I’m better than ever,” she said. 

    View the original article at thefix.com

  • New Generation Of Antidepressants On FDA Fast Track

    New Generation Of Antidepressants On FDA Fast Track

    The medications, which are still in development, may be able to help those who have not found success with currently available antidepressants.

    Pharmaceutical companies are honing in on the potential of ketamine and more to provide fast-acting antidepressant relief, Healthline reports.

    Two examples are Janssen Pharmaceuticals’ esketamine nasal spray and Allergan’s rapastinel (a different, but similarly-acting antidepressant to ketamine), both which the FDA has granted fast-track approval.

    On May 5, Janssen (a subsidiary of Johnson & Johnson) announced findings from Phase 3 trials of its esketamine nasal spray. The study administered esketamine (a close relative of ketamine) to adults with treatment-resistant depression, in addition to a “newly initiated oral antidepressant,” and discovered a “statistically significant, clinically meaningful rapid reduction of depressive symptoms” compared to the placebo.

    According to a Johnson & Johnson press release, the yet-to-be-approved esketamine nasal spray has the potential to address a “significant unmet need for the more than 30% of people suffering from major depressive disorder who do not respond to… currently available antidepressants.”

    Ketamine is typically administered as a veterinary anesthetic, but off-label use of the drug has become more popular for pain, post-traumatic stress disorder (PTSD), anxiety and depression, according to CNN.

    The initial findings of Johnson & Johnson’s research, reported by the BBC in April, found that the nasal spray led to “significant” improvements in depressive symptoms in the first 24 hours. By 25 days, the effects had waned, the report noted, but this does not detract the drug’s potential value as a rapid antidepressant treatment to initiate therapy, said the study’s authors.

    Another potential new antidepressant on the fast track for FDA approval is rapastinel, developed by Allergan. Currently the drug has completed Phase 2 trials and is expecting the results of its Phase 3 trials in 2019, according to Healthline.

    These “rapid-acting therapies” have the potential to be “game-changing in the treatment of depression,” said Allergan executive vice president and chief research and development officer David Nicholson, PhD, in a statement to Healthline. He continued, “Our studies so far demonstrated rapid onset of efficacy within one day, which lasts days after a single dose and a low potential for abuse.”

    Another recent report opens even more possibilities for alternative antidepressant therapies. New research demonstrated that psychedelics (specifically LSD, DMT, MDMA and DOI, an amphetamine) showed positive effects on neural plasticity, meaning that neurons were more likely to branch out and connect with one another.

    Ketamine is said to have the same effect.

    This is a positive development for people living with depression, anxiety, substance use disorder, and PTSD, since research has shown that their brain plasticity and neurite growth are less active.

    View the original article at thefix.com